A new treatment to help clear bacterial infections from the lungs
ELD607 Orai1 Antagonist Increases Bacterial Clearance from the Lung
This study is testing a new treatment called ELD607 to help people with hospital-acquired pneumonia clear bacteria from their lungs more effectively, especially those caused by tough-to-treat germs, and it might be given through inhalation to boost your body's ability to fight off these infections.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Eldec Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Durham, UNITED STATES) |
| Project ID | NIH-10453601 on NIH RePORTER |
What this research studies
This research investigates a novel treatment called ELD607, which aims to improve the clearance of bacteria from the lungs in patients with hospital-acquired pneumonia (HAP). The approach focuses on inhibiting a specific ion channel, Orai1, which is involved in inflammation and bacterial infection. By using a peptidomimetic that is more resistant to degradation, the treatment seeks to enhance the body's immune response against antibiotic-resistant bacteria like Pseudomonas aeruginosa and Staphylococcus aureus. Patients may receive this treatment through inhalation, potentially leading to better outcomes in managing severe lung infections.
Who could benefit from this research
Good fit: Ideal candidates for this research would be patients diagnosed with hospital-acquired pneumonia caused by antibiotic-resistant bacteria.
Not a fit: Patients with pneumonia caused by non-resistant bacteria or those who do not have hospital-acquired pneumonia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option for patients suffering from severe bacterial lung infections, particularly those resistant to traditional antibiotics.
How similar studies have performed: While the approach of targeting ion channels for bacterial clearance is innovative, similar strategies have shown promise in other contexts, indicating potential for success.
Where this research is happening
Durham, UNITED STATES
- Eldec Pharmaceuticals, INC. — Durham, United States (Active)
Researchers
- Principal investigator: Tarran, Robert — Eldec Pharmaceuticals, INC.
- Study coordinator: Tarran, Robert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.